Page 7 - TD-1-1

Tumor Discovery

EDITORIAL
Editor’s foreword to the inaugural issue of Tumor

Discovery

Mingzhu Yin *
†
Department of Dermatology, Xiangya Hospital Central South University, China

In the past century, countless oncology researchers have made great efforts to explore
the mysteries of cancer. However, what we know so far is just the tip of the iceberg.
Cancer has always been the most difficult hurdle to overcome in the history of human
medicine, which is one of the leading causes of morbidity and mortality worldwide
[1]
and brings enormous psychological pressure and economic burden to patients.
According to the latest global cancer data released by the International Agency for
Research on Cancer, there were 19.29 million new cancer cases and 9.96 million
cancer deaths in 2020 globally ; the death cases account for 51.6% of new cases.
[2]
Despite the increasing availability of cancer therapeutic options, such as molecular
targeted therapy [3-5] and immunotherapy [6-9] , millions of cancer-induced deaths were
still reported every year [2,10] . Unfortunately, the pathogenesis of cancers still remains
largely obscure, further hampering the efforts to control the prevalence of cancers
worldwide.
Tumor Discovery is a peer-reviewed and open-access journal that aims to present new
cancer research with strong emphasis on fundamental and translational studies. Tumor
Discovery covers topics, such as etiology and pathogenesis of cancer, mechanisms and
molecular pathways underlying cancer initiation and progression, and tumor metastasis
† Professor Mingzhu Yin is one of the and publishes articles that deepen our understanding of tumor pathogenesis and provide
Editors-in-Chief of Tumor Discovery novel ideas for cancer treatment.
*Corresponding author: In this inaugural issue, five articles spanning across a wide range of topics are
Mingzhu Yin
(yinmingzhu2008@126.com) published. Tamoxifen (TMX) is the best clinical option for the treatment of breast
cancer, which may, however, trigger major dose-dependent side effects due to its
Citation: Yin M, 2022, Editor’s
foreword to the inaugural issue of poor solubility. To overcome this difficulty, Majd synthesized targeted magnetic
Tumor Discovery. Tumor Discov, nanoparticles (MNPs) containing folic acid and hyaluronic acid to improve drug
1(1): 86. [11]
https://doi.org/10.36922/an.v1i1.86 delivery of TMX . The release of 81% TMX after 120 h indicated a controlled
pattern of drug release from the modified MNPs. The modified MNPs have the
Received: May 7, 2022 ability to reduce the viability of MDA-MB-231 cells, and the presence of targeting
Published Online: May 11, 2022
agents and smart delivery of TMX could improve drug efficacy and trigger apoptosis
Copyright: © 2022 Author(s). in MDA-MB-231 cells; these findings collectively point to a novel therapy strategy
This is an Open Access article
distributed under the terms of the for breast cancer. Moreover, cancer patients may exhibit symptoms of cognitive
Creative Commons Attribution impairment before, during and even many years after the completion of therapies,
License, permitting distribution,
and reproduction in any medium, negatively impacting the quality of life and functional independence of cancer
[12]
provided the original work is survivors . However, many aspects of the association between cancer and cognitive
properly cited. impairment remain uncertain, and the definitive connection between systemic cancer
Publisher’s Note: AccScience and central nervous system is yet to be established. Therefore, Jiang et al. summarized
Publishing remains neutral with the current evidence on the potential pathophysiology in these patients with cancer-
regard to jurisdictional claims in
published maps and institutional related cognitive impairment (CRCI) and reviewed the knowledge gaps and the
affiliations. potential counteracting strategies, which will provide a theoretical basis for the

Volume 1 Issue 1 (2022) 1 https://doi.org/10.36922/td.v1i1.86